Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 3,850,000 shares, a decline of 8.3% from the December 15th total of 4,200,000 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily trading volume, of 606,000 shares, the days-to-cover ratio is presently 6.4 days.

Jazz Pharmaceuticals Stock Performance

JAZZ traded down $1.44 during trading on Friday, reaching $121.18. The company's stock had a trading volume of 388,542 shares, compared to its average volume of 538,909. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company's fifty day moving average price is $122.78 and its 200-day moving average price is $114.75. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a market capitalization of $7.33 billion, a price-to-earnings ratio of 17.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Piper Sandler reiterated an "overweight" rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research report on Monday, November 18th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Needham & Company LLC restated a "buy" rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $177.00.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,253 shares of company stock worth $1,001,434. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $29,000. EverSource Wealth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. UMB Bank n.a. raised its position in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after acquiring an additional 129 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 121 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its position in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after purchasing an additional 704 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.